Viridian Therapeutics, Inc./DE Investment Income, Interest
Viridian Therapeutics, Inc./DE (VRDN) reported Investment Income, Interest of $8.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE investment income, interest for the quarter ending 2026-06-30 was $8.49M, a 29.70% increase year-over-year.
- Viridian Therapeutics, Inc./DE investment income, interest for the quarter ending 2026-03-31 was $7.87M, a 4.40% increase year-over-year.
- Viridian Therapeutics, Inc./DE investment income, interest for the quarter ending 2025-12-31 was $7.79M, a 8.54% decline year-over-year.
- Viridian Therapeutics, Inc./DE investment income, interest for the quarter ending 2025-09-30 was $5.52M, a 26.53% decline year-over-year.
- Viridian Therapeutics, Inc./DE investment income, interest for fiscal 2025 was $27.40M, a 13.29% decline from fiscal 2024.
- Viridian Therapeutics, Inc./DE investment income, interest for fiscal 2024 was $31.60M, a 73.23% increase from fiscal 2023.
- Viridian Therapeutics, Inc./DE investment income, interest for fiscal 2023 was $18.24M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.49M 10-Q · filed 2026-08-06 | $16.36M 10-Q · filed 2026-08-06 | $24.15M derived: sum of 3 quarters · filed 2026-08-06 | $29.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.87M 10-Q · filed 2026-05-05 | $15.66M derived: sum of 2 quarters · filed 2026-05-05 | $21.18M derived: sum of 3 quarters · filed 2026-05-05 | $27.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.31M derived: sum of 2 quarters · filed 2026-02-26 | $19.86M derived: sum of 3 quarters · filed 2026-08-06 | $27.40M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.52M 10-Q · filed 2025-11-05 | $12.07M derived: sum of 2 quarters · filed 2026-08-06 | $19.61M 10-Q · filed 2025-11-05 | $28.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.55M 10-Q · filed 2026-08-06 | $14.09M 10-Q · filed 2026-08-06 | $22.61M derived: sum of 3 quarters · filed 2026-08-06 | $30.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.54M 10-Q · filed 2026-05-05 | $16.06M derived: sum of 2 quarters · filed 2026-05-05 | $23.57M derived: sum of 3 quarters · filed 2026-05-05 | |
| 2024-12-31 | $8.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.04M derived: sum of 2 quarters · filed 2026-02-26 | $31.60M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $7.51M 10-Q · filed 2025-11-05 | $23.08M 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | $18.24M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |